Literature DB >> 31711264

Acetylcholinesterase Inhibitors Are Associated with Reduced Fracture Risk among Older Veterans with Dementia.

Abayomi N Ogunwale1,2, Cathleen S Colon-Emeric1,2, Richard Sloane1,2, Robert A Adler3,4, Kenneth W Lyles1,2, Richard H Lee1,2.   

Abstract

Acetylcholinesterase inhibitors (AChEIs) have been noted to increase bone density and quality in mice. Human studies are limited but suggest an association with improved bone healing after hip fracture. We examined the relationship between AChEI use and fracture risk in a national cohort of 360,015 male veterans aged 65 to 99 years with dementia but without prior fracture using Veterans Affairs (VA) hospital, Medicare, and pharmacy records from 2000 to 2010. Diagnosis of dementia, any clinical fracture (excluding facial and digital), comorbidities, and medications were identified using ICD-9 and drug class codes. Cox proportional hazard models considering AChEI use as a time-varying covariate and adjusting for fall and fracture risk factors compared the time-to-fracture in AChEI users versus non-AChEI users. Potential confounders included demographics (age, race, body mass index), comorbidities associated with fracture or falls (diabetes, lung disease, stroke, Parkinson's, seizures, etc.) and medications associated with fracture or falls (bisphosphonates, glucocorticoids, androgen deprivation therapy [ADT], proton pump inhibitors [PPIs], selective serotonin receptor inhibitors [SSRIs], etc.). Competing mortality risk was considered using the methods of Fine and Gray. To account for persistent effects on bone density or quality that might confer protection after stopping the medication, we completed a secondary analysis using the medication possession ratio (MPR) as a continuous variable in logistic regression models and also compared MPR increments of 10% to minimal/no use (MPR 0 to <0.10). Among older veterans with diagnosis of dementia, 20.1% suffered a fracture over an average of 4.6 years of follow-up. Overall, 42.3% of the cohort were prescribed AChEIs during the study period. The hazard of any fracture among AChEI users compared with those on other/no dementia medications was significantly lower in fully adjusted models (hazard ratio [HR] = 0.81; 95% confidence interval [CI] 0.75-0.88). After considering competing mortality risk, fracture risk remained 18% lower in veterans using AChEIs (HR = 0.82; 95% CI 0.76-0.89).
© 2019 American Society for Bone and Mineral Research. Published 2019. This article is a U.S. Government work and is in the public domain in the USA. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  AGING; CLINICAL TRIALS; CORTICOSTEROID OSTEOPOROSIS; EPIDEMIOLOGY; HORMONES AND RECEPTORS; OSTEOPOROSIS

Mesh:

Substances:

Year:  2019        PMID: 31711264      PMCID: PMC7215241          DOI: 10.1002/jbmr.3916

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  36 in total

1.  Competing Risks of Fracture and Death in Older Adults with Chronic Kidney Disease.

Authors:  Rasheeda K Hall; Richard Sloane; Carl Pieper; Courtney Van Houtven; Joanne LaFleur; Robert Adler; Cathleen Colón-Emeric
Journal:  J Am Geriatr Soc       Date:  2018-01-10       Impact factor: 5.562

2.  Donepezil regulates energy metabolism and favors bone mass accrual.

Authors:  Hazem Eimar; Sharifa Alebrahim; Garthiga Manickam; Ahmed Al-Subaie; Lina Abu-Nada; Monzur Murshed; Faleh Tamimi
Journal:  Bone       Date:  2015-12-21       Impact factor: 4.398

3.  Signaling through the M(3) muscarinic receptor favors bone mass accrual by decreasing sympathetic activity.

Authors:  Yu Shi; Franck Oury; Vijay K Yadav; Jürgen Wess; X Sherry Liu; X Edward Guo; Monzur Murshed; Gerard Karsenty
Journal:  Cell Metab       Date:  2010-03-03       Impact factor: 27.287

4.  Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.

Authors:  Harish Kavirajan; Lon S Schneider
Journal:  Lancet Neurol       Date:  2007-09       Impact factor: 44.182

Review 5.  Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.

Authors:  Parminder Raina; Pasqualina Santaguida; Afisi Ismaila; Christopher Patterson; David Cowan; Mitchell Levine; Lynda Booker; Mark Oremus
Journal:  Ann Intern Med       Date:  2008-03-04       Impact factor: 25.391

6.  Bone density, vitamin D nutrition, and parathyroid hormone levels in women with dementia.

Authors:  E Kipen; R D Helme; J D Wark; L Flicker
Journal:  J Am Geriatr Soc       Date:  1995-10       Impact factor: 5.562

Review 7.  Cholinesterase inhibitors for Alzheimer's disease.

Authors:  J Birks
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

8.  The nicotinic acetylcholine receptor α7 subunit is an essential negative regulator of bone mass.

Authors:  Kazuaki Mito; Yuiko Sato; Tami Kobayashi; Kana Miyamoto; Eriko Nitta; Atsushi Iwama; Morio Matsumoto; Masaya Nakamura; Kazuki Sato; Takeshi Miyamoto
Journal:  Sci Rep       Date:  2017-03-28       Impact factor: 4.379

9.  Increased risk of hip fractures in patients with dementia: a nationwide population-based study.

Authors:  Hao-Kuang Wang; Chao-Ming Hung; Sheng-Hsiang Lin; Yi-Cheng Tai; Kang Lu; Po-Chou Liliang; Chi-Wei Lin; Yi-Che Lee; Pei-Hsuan Fang; Li-Ching Chang; Ying-Chun Li
Journal:  BMC Neurol       Date:  2014-09-12       Impact factor: 2.474

10.  Effect of acetylcholinesterase inhibitors on post-surgical complications and mortality following a hip fracture: a cohort study.

Authors:  I Tamimi; S A Madathil; A Kezouh; B Nicolau; I Karp; F Tamimi
Journal:  J Musculoskelet Neuronal Interact       Date:  2017-06-01       Impact factor: 2.041

View more
  4 in total

1.  Brain-Derived Acetylcholine Maintains Peak Bone Mass in Adult Female Mice.

Authors:  Yun Ma; Florent Elefteriou
Journal:  J Bone Miner Res       Date:  2020-04-29       Impact factor: 6.741

Review 2.  Non-neuronal Role of Acetylcholinesterase in Bone Development and Degeneration.

Authors:  Xiaohe Luo; Marianne Lauwers; Paul G Layer; Chunyi Wen
Journal:  Front Cell Dev Biol       Date:  2021-01-28

3.  Could vagus nerve stimulation influence bone remodeling?

Authors:  Ahmad Tamimi; Faleh Tamimi; Malik Juweid; Abdelkarim A Al-Qudah; Amira Al Masri; Said Dahbour; Yakub Al Bahou; Abdelatif Shareef; Iskandar Tamimi
Journal:  J Musculoskelet Neuronal Interact       Date:  2021-06-01       Impact factor: 2.041

Review 4.  Orthogeriatric Management: Improvements in Outcomes during Hospital Admission Due to Hip Fracture.

Authors:  Francisco José Tarazona-Santabalbina; Cristina Ojeda-Thies; Jesús Figueroa Rodríguez; Concepción Cassinello-Ogea; José Ramón Caeiro
Journal:  Int J Environ Res Public Health       Date:  2021-03-16       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.